INTELLECTUAL PROPERTY LICENSE AGREEMENT

This Intellectual Property License Agreement ("Agreement") is entered into as of August 20, 2025, by and between:

LICENSOR: NanoTech Materials Research Institute
Address: 3500 Research Park Drive, Cambridge, MA 02138
Represented by: Dr. Susan Patel, Director of Technology Transfer
Email: s.patel@nanotechresearch.edu
("Licensor")

LICENSEE: Advanced Manufacturing Solutions Corp.
Address: 6000 Industrial Boulevard, Pittsburgh, PA 15201
Represented by: Thomas Anderson, Chief Technology Officer
Email: t.anderson@advancedmfg.com
("Licensee")

RECITALS

WHEREAS, Licensor is a leading research institution specializing in advanced nanomaterials and surface coating technologies;

WHEREAS, Licensor has developed and owns certain patented technology related to ultra-durable ceramic nanocoatings for industrial applications ("Licensed Technology");

WHEREAS, Licensee is engaged in the business of manufacturing high-performance industrial components and desires to incorporate the Licensed Technology into its products;

WHEREAS, Licensor desires to grant Licensee a license to use the Licensed Technology, and Licensee desires to obtain such license, on the terms and conditions set forth herein;

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the parties agree as follows:

1. DEFINITIONS

1.1 "Licensed Patents" means:
(a) U.S. Patent No. 11,234,567 entitled "Ceramic Nanocoating Compositions and Methods of Application"
(b) U.S. Patent No. 11,345,678 entitled "Multi-Layer Nanostructured Coatings with Enhanced Durability"
(c) U.S. Patent Application Serial No. 17/987,654 entitled "Self-Healing Nanocoating Systems"
(d) All foreign counterparts and equivalents of the above
(e) All continuations, continuations-in-part, divisionals, reissues, and extensions thereof
Complete list attached as Exhibit A

1.2 "Licensed Know-How" means all technical information, data, specifications, formulations, processes, methods, techniques, and trade secrets related to the Licensed Patents, whether patentable or not, including:
- Coating formulation recipes
- Application process parameters
- Quality control procedures
- Testing methodologies
- Manufacturing best practices

1.3 "Licensed Technology" means collectively the Licensed Patents and Licensed Know-How.

1.4 "Licensed Products" means any products, materials, or components that:
(a) Are covered by one or more Valid Claims of the Licensed Patents, or
(b) Are manufactured using the Licensed Know-How

1.5 "Net Sales" means gross revenues from sale of Licensed Products, less:
- Trade discounts and allowances
- Returns and credits
- Sales and use taxes
- Shipping and insurance costs
- Bad debt written off

1.6 "Field of Use" means industrial applications including:
- Aerospace components
- Automotive parts
- Industrial machinery components
- Medical device components
- Defense and military equipment

Excluded: Consumer electronics, decorative coatings, architectural applications

1.7 "Territory" means:
- United States of America
- Canada
- European Union member states
- Japan
- South Korea
- Australia

1.8 "Valid Claim" means a claim of an issued patent that has not expired, been declared invalid by a court or patent office, or been abandoned.

2. GRANT OF LICENSE

2.1 License Grant
Licensor hereby grants to Licensee:
(a) An exclusive, royalty-bearing license under the Licensed Technology
(b) In the Field of Use
(c) In the Territory
(d) To make, have made, use, sell, offer for sale, and import Licensed Products
(e) With the right to sublicense as specified in Section 2.4

2.2 Exclusivity
This is an EXCLUSIVE license within the Field of Use and Territory. Licensor shall not:
- Grant licenses to third parties in the Field and Territory
- Practice the Licensed Technology in the Field and Territory for commercial purposes
- Compete with Licensee's Licensed Products in the Field and Territory

Licensor retains rights to:
- Practice Licensed Technology for research and educational purposes
- License outside the Field of Use or Territory
- Practice for government-funded research projects

2.3 Retained Rights
Licensor retains:
- Ownership of all Licensed Technology
- Right to practice for non-commercial research
- Right to publish research findings (subject to Section 8)
- Right to grant licenses for non-commercial use

2.4 Sublicensing Rights
Licensee may grant sublicenses to third parties subject to:
(a) Prior written notice to Licensor (consent not required)
(b) Sublicense terms consistent with this Agreement
(c) Sublicense agreements in writing
(d) Licensee remains responsible for sublicensee compliance
(e) Licensor receives royalty reports on sublicensee sales
(f) Sublicenses terminate upon termination of this Agreement

2.5 Improvements
Licensee Improvements: Owned by Licensee, but Licensor receives royalty-free, non-exclusive license for research purposes.

Licensor Improvements: Automatically included in Licensed Technology if within Field of Use.

Joint Improvements: Co-owned with each party having right to use without accounting to the other.

3. TERM AND TERMINATION

3.1 Initial Term: This Agreement commences on August 20, 2025, and continues until the expiration of the last Valid Claim of the Licensed Patents, unless earlier terminated.

3.2 Post-Patent Term: Upon expiration of all Licensed Patents, license becomes perpetual, royalty-free, and irrevocable for Licensed Know-How.

3.3 Termination by Licensee: Licensee may terminate at any time with 180 days written notice.

3.4 Termination for Breach:
Either party may terminate if the other party:
- Materially breaches and fails to cure within 60 days of written notice
- Becomes insolvent or files bankruptcy
- Challenges validity of Licensed Patents (for Licensee only)

3.5 Effect of Termination:
(a) All licenses granted herein terminate immediately
(b) Licensee shall cease manufacturing, using, and selling Licensed Products
(c) Licensee may sell existing inventory for 180 days (with continued royalty payments)
(d) Sublicenses survive if sublicensees pay royalties directly to Licensor
(e) Payment obligations for sales prior to termination continue
(f) Licensee returns or destroys all confidential Licensed Know-How
(g) Accrued obligations and indemnities survive

4. FINANCIAL TERMS

4.1 Upfront License Fee: $500,000 payable within 30 days of Agreement execution (non-refundable, non-creditable)

4.2 Annual Minimum Royalties:
Year 1 (2025-2026): $100,000
Year 2 (2026-2027): $200,000
Year 3 (2027-2028): $300,000
Year 4 and beyond: $400,000

Payable January 31 of each year. Creditable against earned royalties for that year.

4.3 Running Royalties:
Tier 1 - Net Sales $0 to $10M: 5.0%
Tier 2 - Net Sales $10M to $25M: 4.0%
Tier 3 - Net Sales above $25M: 3.0%

Tiers apply progressively (e.g., first $10M at 5%, next $15M at 4%, etc.)

4.4 Sublicense Income: Licensee shall pay Licensor 25% of all sublicense fees and royalties received from sublicensees.

4.5 Milestone Payments:
- First commercial sale: $250,000
- Cumulative Net Sales reach $50M: $500,000
- Cumulative Net Sales reach $100M: $750,000
Payable within 30 days of achievement.

4.6 Patent Prosecution and Maintenance Costs:
Licensee shall reimburse Licensor for:
- Past patent prosecution costs: $125,000 (due within 60 days)
- Ongoing prosecution and maintenance costs for Licensed Patents
- Costs invoiced quarterly with supporting documentation

4.7 Payment Terms:
- Quarterly royalty payments due 45 days after quarter end
- Payments via wire transfer
- Late payments accrue interest at 1.5% per month
- All payments in US Dollars

5. RECORDS AND REPORTING

5.1 Records: Licensee shall maintain complete and accurate records of:
- Licensed Product sales
- Net Sales calculations
- Sublicense agreements and payments
- Milestone achievements

5.2 Quarterly Reports: Due 30 days after each quarter end, including:
- Gross sales and Net Sales by product and country
- Royalty calculations
- Sublicense income
- Number of units sold
- Milestone progress

5.3 Annual Reports: Due 60 days after year end, including:
- Comprehensive financial summary
- Market analysis and forecasts
- Product development updates
- Sublicensee activities

5.4 Audit Rights:
Licensor may audit Licensee's records:
- Once per year upon 30 days notice
- During business hours
- At Licensor's expense (unless underpayment >5%, then Licensee pays)
- By independent certified accountant
- Subject to confidentiality obligations

6. DILIGENCE OBLIGATIONS

6.1 Development Milestones:
- Within 12 months: Complete product development and testing
- Within 18 months: Obtain necessary regulatory approvals
- Within 24 months: First commercial sale of Licensed Product
- Within 36 months: Achieve Net Sales of at least $5 million

6.2 Commercialization Efforts:
Licensee shall use commercially reasonable efforts to:
- Develop Licensed Products
- Obtain regulatory approvals
- Market and sell Licensed Products
- Expand into all major markets in Territory

6.3 Failure to Meet Milestones:
If Licensee fails to meet milestone, Licensor may:
- Convert license from exclusive to non-exclusive (with 90 days to cure)
- Reduce Territory
- Terminate Agreement (after 2 consecutive failures)

6.4 Reports: Licensee shall provide semi-annual diligence reports detailing progress.

7. INTELLECTUAL PROPERTY MANAGEMENT

7.1 Patent Prosecution:
Licensor Controls: Licensor shall have first right to prosecute and maintain Licensed Patents.
Licensee Input: Licensee may provide comments and suggestions.
Licensee Costs: Licensee reimburses all reasonable prosecution and maintenance costs.
Abandonment: If Licensor decides to abandon any Licensed Patent, Licensee has right to assume prosecution at own expense.

7.2 Patent Enforcement:
(a) Notice: Each party shall promptly notify the other of any suspected infringement.

(b) Licensee First Right: Licensee has first right to enforce Licensed Patents against infringers:
- 90 days to decide whether to sue
- Licensee controls litigation and bears costs
- Licensor cooperates and may join as party
- Licensee retains recoveries after costs; remainder split 70/30 (Licensee/Licensor)

(c) Licensor Backup Right: If Licensee declines or fails to sue within 90 days:
- Licensor may enforce at own expense
- Licensor retains all recoveries after costs

(d) Settlement: Neither party may settle without other's consent (not unreasonably withheld).

7.3 Defense of Patents:
(a) If Licensed Patents challenged (IPR, reexamination, opposition):
- Licensor has right to defend
- Licensee reimburses reasonable costs
- Licensee may participate at own expense

(b) Licensee may not challenge validity of Licensed Patents (no-challenge clause).

8. CONFIDENTIALITY

8.1 Confidential Information: Licensed Know-How and business terms of this Agreement are confidential.

8.2 Obligations: Each party shall:
- Protect confidential information with reasonable care
- Not disclose except to employees, sublicensees, and advisors with need to know
- Use confidential information only for permitted purposes
- Not reverse engineer Licensed Technology

8.3 Exceptions: Standard exceptions for publicly known, independently developed, or rightfully received information.

8.4 Publication: Licensor may publish research findings after giving Licensee 60 days to review and request redaction of confidential information.

8.5 Duration: Confidentiality obligations survive termination for 10 years.

9. WARRANTIES AND REPRESENTATIONS

9.1 Licensor Warrants:
(a) Ownership of Licensed Technology
(b) Authority to grant license
(c) Licensed Patents are valid and enforceable (to Licensor's knowledge)
(d) No conflicting agreements
(e) No knowledge of infringement by Licensed Technology

9.2 DISCLAIMER: EXCEPT AS EXPRESSLY STATED, LICENSED TECHNOLOGY PROVIDED "AS IS" WITHOUT WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

9.3 Licensee Warrants:
(a) Authority to enter Agreement
(b) Compliance with all applicable laws
(c) Proper use of Licensed Technology

10. INDEMNIFICATION AND LIABILITY

10.1 Licensee Indemnity:
Licensee shall indemnify and hold harmless Licensor from claims arising from:
- Manufacture, use, or sale of Licensed Products
- Breach of this Agreement
- Negligence or willful misconduct
- Product liability claims
- Regulatory violations

10.2 Licensor Indemnity:
Licensor shall indemnify Licensee from third-party claims that Licensed Technology infringes third-party intellectual property rights.

10.3 Indemnification Procedures:
- Prompt written notice of claim
- Indemnifying party controls defense
- Indemnified party cooperates
- No settlement without consent

10.4 Limitation of Liability:
EXCEPT FOR INDEMNIFICATION OBLIGATIONS, NEITHER PARTY LIABLE FOR CONSEQUENTIAL, INCIDENTAL, OR PUNITIVE DAMAGES.

Licensor's total liability capped at fees received in 12 months prior to claim.

11. INSURANCE

Licensee shall maintain insurance:
- Product Liability: $10 million per occurrence
- General Liability: $5 million
- Professional Liability: $5 million

Licensor named as additional insured. Certificates provided annually.

12. REGULATORY COMPLIANCE

12.1 Licensee responsible for obtaining all regulatory approvals for Licensed Products.

12.2 Compliance with FDA, EPA, OSHA, and all applicable regulations.

12.3 Export Controls: Compliance with export control laws. No export to embargoed countries.

13. QUALITY CONTROL AND TRADEMARK

13.1 Quality Standards: Licensed Products shall meet industry standards and specifications provided by Licensor.

13.2 Trademark License: Licensor grants Licensee non-exclusive right to use "NanoTech Certified" mark on Licensed Products meeting quality standards.

13.3 Quality Control: Licensor may inspect facilities and test products to ensure quality (with reasonable notice).

13.4 Recall: Licensee responsible for product recalls. Must notify Licensor within 24 hours.

14. GENERAL PROVISIONS

14.1 Governing Law: Commonwealth of Massachusetts

14.2 Dispute Resolution:
- Good faith negotiations (30 days)
- Mediation in Boston, MA (60 days)
- Binding arbitration under AAA rules

14.3 Entire Agreement: This Agreement (including Exhibits) constitutes entire agreement and supersedes all prior agreements.

14.4 Amendment: Must be in writing signed by both parties.

14.5 Assignment:
- Licensee may not assign without prior written consent
- Licensor may assign to successor institution
- Assignment to acquirer of Licensee permitted with notice

14.6 Force Majeure: Neither party liable for delays due to events beyond reasonable control.

14.7 Notices: Written notices to addresses above via email (confirmed) or certified mail.

14.8 Severability: Invalid provisions severed; remaining provisions remain in effect.

14.9 Relationship: Parties are independent contractors, not partners or joint venturers.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

LICENSOR: NANOTECH MATERIALS RESEARCH INSTITUTE

Signature: _________________________
Name: Dr. Susan Patel
Title: Director of Technology Transfer
Date: August 20, 2025


LICENSEE: ADVANCED MANUFACTURING SOLUTIONS CORP.

Signature: _________________________
Name: Thomas Anderson
Title: Chief Technology Officer
Date: August 20, 2025
